- Melatonin is produced in large amounts by the gut itself — not just the brain — and plays a real role in regulating intestinal movement.
- Early human studies suggest melatonin may reduce symptoms in irritable bowel syndrome (IBS), particularly abdominal pain and disturbed motility, but trial sizes are small and results are mixed.
- Evidence in healthy adults for straightforward "speed up or slow down" motility effects is weak and inconsistent; we don't yet have enough data to recommend melatonin purely as a gut-motility agent.
- People who are pregnant, taking blood thinners, or on immunosuppressants should avoid supplemental melatonin without medical guidance.
What the evidence shows
Melatonin's reputation is almost entirely tied to sleep, but gastroenterologists have been quietly interested in it for decades — and for good reason. The gastrointestinal tract contains roughly 400 times more melatonin than the pineal gland (Bubenik, 2002), which immediately suggests it does something there beyond helping you drift off.
The strongest human evidence comes from IBS research. A randomized controlled trial by Song et al. (2005) gave 3 mg of melatonin nightly to IBS patients and found significant reductions in abdominal pain and rectal hypersensitivity compared to placebo, with some improvement in bowel habit. A follow-up trial by Lu et al. (2005) replicated the pain-reduction finding in a predominantly female IBS group. These are promising signals, but both studies enrolled fewer than 100 participants — not the scale needed to draw firm conclusions.
A Cochrane-style systematic review by Siah et al. (2014) looked across available IBS and functional GI trials and concluded that melatonin consistently reduced abdominal pain but that motility effects (how fast or slow stool moves) were inconsistent across studies. Some participants showed accelerated transit; others showed no change. The review called for larger, better-controlled trials — which, as of this writing, still haven't fully arrived.
In animal models, melatonin clearly modulates colonic contractility and transit time (Storr et al., 2002), but animal physiology doesn't always translate cleanly to humans. For healthy adults without a GI disorder, there is currently no reliable clinical evidence that supplemental melatonin meaningfully speeds up or slows down gut transit. If your interest is purely motility optimization in the absence of a diagnosed condition, the evidence doesn't support spending money on this.
How it works (mechanism)
Melatonin acts on at least two receptor subtypes (MT1 and MT2) that are expressed throughout the gut wall, including in the enteric nervous system — the "second brain" embedded in your intestinal lining. Activation of these receptors appears to modulate smooth muscle contraction and may influence how the gut responds to serotonin, itself a major driver of intestinal movement (Bubenik, 2002).
The gut-brain axis adds another layer: because the gut and pineal gland are in chemical conversation, disrupted circadian rhythms (shift work, jet lag, chronic poor sleep) measurably alter GI motility in humans (Kaji et al., 2021). Melatonin supplementation in these contexts might partly restore normal motility patterns — but this is a different claim than "melatonin speeds up digestion," and it only applies when the underlying rhythm is disrupted.
Melatonin also has anti-inflammatory and antioxidant properties in the gut mucosa, which may explain its effects on visceral pain in IBS more than motility per se (Chojnacki et al., 2010).
Dose & timing if you try it
If you have IBS and are considering a trial under medical supervision, the doses used in the human studies above were 3 mg taken at bedtime. This timing is deliberate: it mirrors the body's natural melatonin rise and may help resynchronize gut circadian rhythms overnight.
Trial duration in positive studies ranged from 4 to 8 weeks. Shorter trials are unlikely to show meaningful changes in bowel habit patterns. Over-the-counter products often sell doses of 5–10 mg, but higher doses have not demonstrated better GI outcomes and produce more next-day grogginess; 0.5–3 mg is generally considered adequate for any melatonin application (Buscemi et al., 2006).
Do not self-prescribe melatonin for a GI complaint without ruling out other causes. Changes in gut motility can be a sign of conditions (thyroid disease, celiac, inflammatory bowel disease) that need proper diagnosis first.
Who should skip it
- Pregnant and breastfeeding individuals: Safety data in these populations is insufficient. Melatonin crosses the placenta and is present in breast milk.
- People taking blood thinners (warfarin, heparin): Melatonin may potentiate anticoagulant effects, raising bleeding risk (Siah et al., 2014).
- People on immunosuppressants or corticosteroids: Melatonin can interact with immune-modulating medications.
- Children and adolescents: GI use hasn't been adequately studied in this group; long-term hormonal effects are unknown.
- People with autoimmune conditions: Melatonin has immune-stimulating properties that may be counterproductive.
- People with epilepsy: Some evidence suggests melatonin can interact with seizure threshold and anticonvulsant medications.
Bottom line
Melatonin has a biologically credible role in gut function — the receptor distribution and the sheer volume of melatonin made in the gut make it genuinely interesting. For people with IBS-related abdominal pain, the small trials available hint at a modest benefit, particularly for pain and possibly for normalizing disordered motility. That's worth discussing with a gastroenterologist.
For everyone else — people hoping melatonin will fix sluggish digestion, speed transit, or resolve constipation without an underlying circadian or IBS-related cause — the evidence is not there yet. Save your money until larger, better-designed trials clarify who actually benefits. This is a "watch this space" supplement for gut motility, not a proven one.
References
- Bubenik, G. A. (2002). Gastrointestinal melatonin: Localization, function, and clinical relevance. Digestive Diseases and Sciences, 47(10), 2336–2348.
- Buscemi, N., et al. (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction. BMJ, 332(7538), 385–393.
- Chojnacki, C., et al. (2010). Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. Journal of Physiology and Pharmacology, 61(3), 327–334.
- Kaji, I., et al. (2021). Peripheral serotonin and melatonin in gut function and circadian regulation. Frontiers in Neuroscience, 15, 649755.
- Lu, W. Z., et al. (2005). Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: A double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics, 22(10), 927–934.
- Siah, K. T. H., et al. (2014). Melatonin for the treatment of irritable bowel syndrome. World Journal of Gastroenterology, 20(10), 2492–2498.
- Song, G. H., et al. (2005). Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: A randomised, double blind, placebo controlled study. Gut, 54(10), 1402–1407.
- Storr, M., et al. (2002). Melatonin inhibits contractility of guinea pig smooth muscle. Scandinavian Journal of Gastroenterology, 37(1), 34–40.